Common use of Facility Program Clause in Contracts

Facility Program. In consideration of Nordion establishing the Facility, Molecular Insight Pharmaceuticals will pay to Nordion a non-reimbursable facility fee of [**********************] United States dollars (US $[********]) upon execution of this Agreement. After the Facility is completed, Nordion shall, in consultation with Molecular Insight Pharmaceuticals, develop and implement a Master Validation Plan for the Facility that will allow the production of BMIPP under cGMPs in the volumes required by Molecular Insight Pharmaceuticals for Phase III clinical supply as described in Section 4.1. The costs of preparation, development and implementation of the Master Validation Plan will be borne by Nordion. Prior to implementation, both parties shall in writing approve the Master Validation Plan. Nordion shall ensure that the Facility is available for the production of BMIPP for supply to Molecular Insight Pharmaceuticals on a priority basis at least three days per week to be mutually agreed between the parties.